Pharmascience Acquires Aegera to Facilitate R&D

Pharmascience, the largest generic pharmaceutical company in Quebec, announced last Friday the acquisition of Aegera Therapeutics Inc., a Montreal-based clinical-stage biotechnology company.

Quebec-based generic pharmaceutical company Pharmascience has acquired Aegera Therapeutics, a Montreal-based clinical-stage biotechnology company focused on developing therapeutics to address unmet medical needs, primarily in oncology.

Under the acquisition agreement, Aegera’s 20 employees will join Pharmascience.

"The acquisition of Aegera will enable Pharmascience to increase and diversify its research and development activities through the continuance of Aegera’s programs,” said David Goodman, chief executive officer of Pharmascience. This acquisition will strengthen Pharmascience’s position as a pharmaceutical leader, and will solidify our organization’s diversification and expansion strategy.”